SPONSOR
Mabwell (Shanghai) Bioscience Co., Ltd.
Total Trials
6
Recruiting
6
Phases
Phase 1, Phase 2, Phase 3, Phase 1, Phase 2
Conditions studied: Polycythemia VeraScarUrothelial CarcinomaTriple-Negative Breast CancerAdvanced Urothelial CarcinomaSolid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd. is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Polycythemia Vera, Scar, Urothelial Carcinoma, Triple-Negative Breast Cancer.
The trial portfolio spans Phase 1, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Mabwell (Shanghai) Bioscience Co., Ltd.
How many clinical trials has Mabwell (Shanghai) Bioscience Co., Ltd. sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by Mabwell (Shanghai) Bioscience Co., Ltd., of which 6 are actively recruiting participants. These trials cover conditions including Polycythemia Vera, Scar, Urothelial Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Mabwell (Shanghai) Bioscience Co., Ltd. research focus on?
Mabwell (Shanghai) Bioscience Co., Ltd. clinical trials span Polycythemia Vera, Scar, Urothelial Carcinoma, Triple-Negative Breast Cancer, Advanced Urothelial Carcinoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Mabwell (Shanghai) Bioscience Co., Ltd. clinical trial?
To participate in a Mabwell (Shanghai) Bioscience Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Mabwell (Shanghai) Bioscience Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Mabwell (Shanghai) Bioscience Co., Ltd.
NCT06752746 Phase 1
Recruiting
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Polycythemia Vera
NCT07576608 Phase 2
Recruiting
A Phase II Study of 9MW3811 in Patients With Pathological Scar
Scar
NCT06592326 Phase 3
Recruiting
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Urothelial Carcinoma
NCT06492005 Phase 2
Recruiting
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
NCT06196736 Phase 3
Recruiting
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Advanced Urothelial Carcinoma
NCT07265622 Phase 1, Phase 2
Recruiting
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Solid Tumors
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology